Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid Subsequent to Denosumab in Osteoporosis
NCT03087851Phase 4Completed
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteoporosis (3 arms), sponsored by Aarhus University Hospital. Primary endpoints: Change in Lumbar Spine BMD From Baseline to 6 Months After the Zoledronic Acid Infusion and Number of Participants Who Fail to Maintain BMD at 2 years. Started Mar 2017; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03087851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03087851.